Molecular Diagnostics Market worth $32.56 billion by 2031
The report "Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application (Infectious, Cancer), Technique, Clinical Application, End User- Global Forecast to 2031" The molecular diagnostics market is estimated at USD 21.68 billion in 2026 and is projected to reach USD 32.56 billion by 2031 at a CAGR of 8.5% during the forecast period.
Browse 450 market data Tables and 150 Figures spread through 300 Pages and in-depth TOC on "Molecular Diagnostics Market by Product & Service (Kits, Instruments, Software), Test Type (Lab, PoC), Sample (Blood, Urine), Technology (PCR, NGS, ISH), Application (Infectious, Cancer), Technique, Clinical Application, End User- Global Forecast to 2031"
View detailed Table of Content here - https://www.marketsandmarkets.com/Market-Reports/molecular-diagnostic-market-833.html
The molecular diagnostics market is experiencing steady growth, supported by several key factors. One primary driver is rising research and development funding, which is accelerating innovation and enabling the development of more advanced testing technologies. At the same time, increasing awareness of the benefits of early disease detection, especially for infections and cancer, encourages patients and providers to rely more on molecular testing. These tests offer faster, more accurate results, helping guide treatment decisions. The growing emphasis on personalized medicine also contributes to the market’s expansion. As healthcare access and infrastructure improve in emerging economies, molecular diagnostics is becoming more widely adopted across different settings. As these trends continue, the market is expected to grow in the coming years.
Lab Tests Led the Market in 2025 on the Strength of Centralized, High-Throughput Testing
By test type, the molecular diagnostics market is segmented into lab tests and PoC tests. Lab tests held the largest share in 2025, largely because molecular testing is widely performed in centralized laboratories that handle large patient volumes and rely on advanced, high-throughput platforms. These tests offer high accuracy and sensitivity, along with extensive assay menus, making them well suited to complex applications such as cancer diagnostics, genetic screening, and infectious disease detection. They also integrate smoothly into hospital and reference laboratory workflows, supported by trained staff and established quality control protocols. Ongoing advances in automated systems and multiplex technologies further improve lab testing efficiency. Together with their established infrastructure and proven clinical reliability, these strengths continue to sustain the segment's dominance.
Blood, Serum, and Plasma Are Expected to Be the Fastest-Growing Sample Type During the Forecast Period
By sample type, the molecular diagnostics market is segmented into blood, serum and plasma, urine, and other samples. The blood, serum, and plasma segment is expected to grow the fastest over the forecast period. This growth is driven by the broad clinical utility of these samples for detecting infectious diseases, genetic disorders, and cancer. These samples are widely accepted in clinical practice because they are reliable, easy to collect, and compatible with many molecular testing platforms. Advances in liquid biopsy and noninvasive testing methods further encourage the use of blood-based diagnostics. As the need for accurate, minimally invasive testing rises, the segment is likely to continue expanding rapidly.
North America is the Largest Regional Market for Molecular Diagnostics
The molecular diagnostics market is divided into five geographic regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. North America is expected to be the largest regional market, supported by robust healthcare infrastructure and strong adoption of advanced testing technologies. The region bears a considerable burden of infectious diseases, cancer, and genetic disorders, driving demand for accurate and timely diagnostics. Supportive regulatory policies and steady investment in research and development also contribute to market growth. Leading diagnostic companies and well-equipped laboratories enable the deployment of molecular tests at scale across hospitals and diagnostic centers, improving patient access to timely and reliable results.
Major players in the molecular diagnostics market include Danaher Corporation (US), F. Hoffmann-La Roche Ltd. (Switzerland), Hologic, Inc. (US), Illumina, Inc. (US), Abbott (US), bioMérieux (France), Thermo Fisher Scientific Inc. (US), QIAGEN N.V. (Netherlands), Revvity, Inc. (US), Myriad Genetics, Inc. (US), Siemens Healthineers AG (Germany), Becton, Dickinson and Company (BD) (US), Grifols, S.A. (Spain), QuidelOrtho Corporation (US), DiaSorin S.p.A. (Italy), Exact Sciences Corporation (US), Genetic Signatures (Australia), Agilent Technologies, Inc. (US), MDxHealth (Belgium), Biocartis (Belgium), Bruker (US), TBG Diagnostics Limited (Australia), Amoy Diagnostics Co., Ltd. (China), Vela Diagnostics (Singapore), Molbio Diagnostics Limited (India), geneOmbio Technologies (India), Savyon Diagnostics (Israel), and Uniogen OY (Finland).
About MarketsandMarkets™
MarketsandMarkets™ has been recognized as one of America's Best Management Consulting Firms by Forbes, as per their recent report.
MarketsandMarkets™ is a blue ocean alternative in growth consulting and program management, leveraging a man-machine offering to drive supernormal growth for progressive organizations in the B2B space. With the widest lens on emerging technologies, we are proficient in co-creating supernormal growth for clients across the globe.
Today, 80% of Fortune 2000 companies rely on MarketsandMarkets, and 90 of the top 100 companies in each sector trust us to accelerate their revenue growth. With a global clientele of over 13,000 organizations, we help businesses thrive in a disruptive ecosystem.
The B2B economy is witnessing the emergence of $25 trillion in new revenue streams that are replacing existing ones within this decade. We work with clients on growth programs, helping them monetize this $25 trillion opportunity through our service lines – TAM Expansion, Go-to-Market (GTM) Strategy to Execution, Market Share Gain, Account Enablement, and Thought Leadership Marketing.
Built on the 'GIVE Growth' principle, we collaborate with several Forbes Global 2000 B2B companies to keep them future-ready. Our insights and strategies are powered by industry experts, cutting-edge AI, and our Market Intelligence Cloud, KnowledgeStore™, which integrates research and provides ecosystem-wide visibility into revenue shifts.
To find out more, visit www.MarketsandMarkets™.com or follow us on Twitter , LinkedIn and Facebook .
Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA: +1-888-600-6441
Email: [email protected]
Visit Our Website: https://www.marketsandmarkets.com
- Triangulate with your Own Data
- Get Data as per your Format and Definition
- Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
- Any level of Personalization
- What are the Known and Unknown Adjacencies Impacting the Molecular Diagnostics Market
- What will your New Revenue Sources be
- Who will be your Top Customer; what will make them switch
- Defend your Market Share or Win Competitors
- Get a Scorecard for Target Partners
